Long-term survival in patients treated for testicular seminoma.
Forty-eight patients with newly-diagnosed testicular seminomas were followed for a mean of 7 years after treatment. At the time of diagnosis, seminoma was confined to testis in 74% (36) and was metastatic to retroperitoneal lymph nodes in 15% (7) and to distant nodal sites or parenchymal organs in 10% (5). Ninety-six percent remained free of disease, 94% in first complete remission (CR) and 2% after treatment of first recurrence. Long-term disease-free survival in CR per stage was 97% (35/36) for Stage I, 100% for Stage II, and 80% (4/5) for Stage III. However, three patients, who received prior chest radiation therapy (RT), died from acute myocardial infarction 2, 9, and 10 years after treatment and while free of disease.
Hannun
Y
Y
Division of Hematology and Oncology, Duke University Medical Center, Durham, North Carolina.
Vugrin
D
D
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000401:mortality* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy